An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell lineAzmi Yerlikaya(Dumlupinar University), Emrah Okur(Dumlupinar University)CytotechnologyDecember 20, 201910.1007/s10616-019-00362-xCited by 13SaveCiteExport RISWatch citationsRelated PapersA novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib|Oncology Letters|2016|22